VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “ Company ” or “ Algernon ”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial, which may be informative for the Company’s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough.
The Company reports that in the COVID-19 trial, one of the biomarkers that was measured was the change in IL-6 levels. In the measurement from baseline to day five, IL-6 was reduced in the 20 mg treatment arm by 267 ng/L, versus 7 ng/L in the standard of care arm (values are adjusted mean concentrations; p = 0.0292).
IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine and is encoded by the IL-6 gene. IL-6 can promote fibrosis by driving chronic inflammation and is elevated in patients with IPF. 1 Blockade of IL-6 has been shown to attenuate pulmonary fibrosis in a mouse model. 2
The effects of Ifenprodil on IL-6 may be helpful in better understanding its potential role as a possible therapeutic treatment for IPF.
The company recently announced it had achieved 50% of its enrollment target for its Phase 2 trial of Ifenprodil for IPF and chronic cough. Changes in IL-6 will be measured in this study, along with other markers of fibrosis such as C-reactive protein and collagen pro-peptides.
The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time.
1. https://www.nature.com/articles/s41420-021-00437-9
2. https://www.jimmunol.org/content/193/7/3755.long
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com .
The CSE does not accept responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
